A strategic cooperation agreement was signed between the South China Center for Innovative Pharmaceuticals (SCCIP) and Danaher Life Science Platform, China on Jan 14 to carry out cooperation in areas like biomedical technology services.
Danaher, headquartered in the United States, is a Fortune 500 company and a pioneer in life sciences around the world. Danaher Life Science Platform, China was set up in June 2019, aiming to offer better products and services for Chinese customers.
Li Bing, president of Danaher Life Science Platform, China, said that the platform currently owns seven brands and offers integrated solutions for its four businesses, including instruments and technical services.
SCCIP has a solid foundation in areas in the research and development of new medicines, professional techniques services, as well as incubator services after decades of growth. It is expected to push forward the construction of a technological service platform for a full industrial chain in biomedicine.
GDD, as a core area for Guangzhou's biomedical industry, has clustered more than 1,000 biomedical companies, accounting for about 60 percent of Guangzhou's total industrial scale.